ABCB5 and melanoma: shRNA against ABCB5 or anti-ABCB5 mAb on G3361 melanoma cells decreased cancer cell survival to dacarbazine, paclitaxel, teniposide, docetaxel, etoposide, doxorubicin, and vincristine[53].